Cencora, Inc. (COR)
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model
Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth.
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?
COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.
Cencora Launches Enhanced Nucleus Solution for Specialty Practices
COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.
Cencora's Specialty Supply Chain: Where COR's Growth Is Headed
COR bets on MSOs, specialty logistics and AI tools to deepen ties beyond distribution???even as GLP-1 mix and pricing swings cloud results.
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know
The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora Q2 Earnings Call Highlights
Cencora NYSE: COR reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-year revenue growth expectations, citing faster-than-anticipated brand conversions at a large mail-order pharmacy customer and slower expected growth in GLP-1 products.
Cencora Earnings Review: The Selloff Was Overdone In My View
Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss. Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions. Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services.
